Solriamfetol and CBT-I in Patients With Insomnia Disorder
Status:
Not yet recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
Medication is FDA approved. The objective of this project is to test the efficacy of
solriamfetol for treating insomnia (alone and in combination with Cognitive Behavioral
Therapy for Insomnia [CBT-I]). Ultimately, this study will test whether wake extension
(regardless of how it is achieved) will consolidate sleep and improve sleep continuity.